This site uesd JavaScript.
TOP
>
News Release
> list in 2008
Back Number
2010
2009
2008
2007
2006
2005
Browse by Category
Corporate
R&D
Products
Others
2008.12.25
Daiichi Sankyo Enters Alliance with The Kitasato Institute
HTML
PDF
2008.12.19
Ranbaxy Reconstitutes Board of Directors following Strategic Alliance with Japanfs Daiichi Sankyo
Ranbaxy CEO and Managing Director Malvinder Mohan Singh Takes Additional Role as Chairman of the Board
HTML
PDF
2008.12.19
Announcement regarding ActHib®(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b) launch
HTML
PDF
2008.12.19
Prasugrel Receives Positive Opinion from the European Committee for Medicinal Products for Human Use (CHMP)
HTML
PDF
2008.12.11
Daiichi Sankyo Submits Application for Approval of CS-866AZ Antihypertensive Combination Drug in Japan
HTML
PDF
2008.12.08
NEW PHASE II DATA SHOW SAFETY OF ONCE-DAILY ORAL FACTOR Xa INHIBITOR, DU-176b, COMPARABLE TO WARFARIN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
HTML
PDF
2008.11.26
DAIICHI SANKYO sets up subsidiary in Ireland
Critical step in European expansion
HTML
PDF
2008.11.17
DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options (Stock Acquisition Rights) as Remuneration
HTML
PDF
2008.11.17
Start of Phase III Trial on the Anti-influenza Drug CS-8958
HTML
PDF
2008.11.13
Daiichi Sankyo's Research Foundation Establishes First Annual Clinical Pharmacology Research Award
HTML
PDF
2008.11.13
DAIICHI SANKYO EUROPE GmbH announce SEVIKAR® a new fixed dose combination treatment for essential hypertension
HTML
PDF
2008.11.11
ARQULE AND DAIICHI-SANKYO ENTER INTO STRATEGIC R&D PARTNERSHIP TO PROGRESS NOVEL COMPOUNDS TO TARGET CANCER
Product development agreement focused on ARQ 197, c-Met inhibitor,with discovery collaboration directed toward novel kinase inhibitors;
HTML
PDF
2008.11.10
Announcement regarding ActHib(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b)launch date
HTML
PDF
2008.11.07
Ranbaxy and Daiichi Sankyo Successfully Complete Landmark Deal
HTML
PDF
2008.10.31
DAIICHI SANKYO to Dissolve Subsidiaries with Sanofi-aventis
HTML
PDF
2008.10.31
DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as Remuneration
HTML
PDF
2008.10.23
UK Levofloxacin SPC and Underlying Patent Upheld by High Court Patent Court
HTML
PDF
2008.10.20
Daiichi Sankyo and Ranbaxy Move Forward Toward
The Completion of the Landmark Deal
HTML
PDF
2008.10.17
Daiichi Sankyo and Lilly Respond to Speculation
On Status of Prasugrel New Drug Application
HTML
PDF
2008.10.17
Result of the Open Offer for Shares in Ranbaxy Laboratories Limited
HTML
PDF
2008.09.30
Daiichi Sankyo Subsidiary to Close Osaka Plant
HTML
PDF
2008.09.30
Announcement regarding ActHib(R)(pediatric vaccine for the prevention of infections caused by Haemophilus influenza Type b)
HTML
PDF
2008.09.27
FDA Continues to Review Prasugrel New Drug Application
HTML
PDF
2008.09.24
Notice regarding The Open Offer for Shares in Ranbaxy Laboratories Limited
HTML
PDF
2008.09.02
Daiichi Sankyo Announces Clinical Study Data for
Oral Factor Xa Inhibitor DU-176b
HTML
PDF
2008.08.29
DAIICHI SANKYO Announces Cancellation of Treasury Stocks
HTML
PDF
2008.08.26
DAIICHI SANKYO Notice on Organizational Restructuring
as of October 1, 2008
HTML
PDF
2008.08.25
Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events
HTML
PDF
2008.08.11
DAIICHI SANKYO to Launch Open Offer for Ranbaxy Laboratories Limited
HTML
PDF
2008.08.04
DAIICHI SANKYO Announces Results of Share Buyback
HTML
PDF
Next
Back Number
2010
2009
2008
2007
2006
2005
Browse by Category
Corporate
R&D
Products
Others